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Nutrient overload leads to obesity, insulin resistance, and often type 2 diabetes. Whereas increased fat intake is commonly
cited as the major factor in diet-induced dysmetabolic states, increased protein consumption also contributes, through
elevated circulating amino acids. Recent studies have revealed that ribosomal protein S6 kinase 1, S6K1, an effector of
mTOR, is sensitive to both insulin and nutrients, including amino acids. Although S6K1 is an effector of growth, recent
reports show that amino acids also negatively affect insulin signaling through mTOR/S6K1 phosphorylation of IRS1. More-
over, rather than signaling through the class 1PI3Kpathway, amino acids appear tomediatemTORactivation through class 3
PI3K, or hVps34. Consistent with this, infusion of amino acids into humans leads to S6K1 activation, inhibition of insulin-
induced class 1 PI3K activation, and insulin resistance. Thus, S6K1 may mediate deleterious effects, like insulin resistance,
and potentially type 2 diabetes in the face of nutrient excess.Introduction
It is hypothesized that during evolution the scarcity of food led to
the development of dominant genetic mechanisms to secure
and manage caloric intake, mechanisms which prevailed over
those that suppressed food intake (Neel, 1999). In Western
societies, the increase in food availability has exposed these
dominant genetic traits, with obesity emerging as a prevalent
metabolic disorder (Must et al., 1999). One important patho-
genic consequence of obesity is insulin resistance, which plays
a central role in the development of type 2 diabetes and the on-
set of cardiovascular disease, both major causes of morbidity
and rising heath care costs in western societies (Morgan et al.,
2004). Thus, nutrient overload, in conjunction with genetic pre-
dispositions, may play a key role in the development of insulin
resistance. Furthermore, while increased fat intake is frequently
considered to be the major cause of metabolic abnormalities
due to overnutrition, there is increasing evidence that elevated
dietary protein consumption also contributes to this syndrome
(Krebs, 2005). This observation is consistent with the approxi-
mate 33% rise in the consumption of processed meat over
the last 50 years and with the association of high-protein diets
with glucose intolerance, insulin resistance, and an increased
incidence of type 2 diabetes (Linn et al., 1996, 2000; Schulze
et al., 2003; Song et al., 2004). Moreover, in insulin-resistant
states of obesity, plasma concentrations of amino acids are
elevated, particularly branched-chain amino acids (Felig et al.,
1969, 1970, 1974). These findings are in agreement with studies
demonstrating that the infusion of amino acids induces insulin
resistance in experimental settings, similar to what is observed
with lipid administration (Krebs et al., 2002, 2003). These find-
ings raise the possibility of a broad role for dietary protein ex-
cess in metabolic disease. Therefore the molecular mechanisms
by which excess amino acids lead to the development of insulin
resistance have important implications for public health and
clinical medicine. Here we review recent evidence demonstrat-
ing that ribosomal protein S6 kinase 1 (S6K1), a component ofCELL METABOLISM 3, 393–402, JUNE 2006 ª2006 ELSEVIER INC. Dthe insulin signal transduction pathway, through negatively reg-
ulating IRS1 function (Zick, 2004), may be a key molecular ele-
ment in driving insulin resistance under conditions of nutrient
overload (Patti and Kahn, 2004; Harrington et al., 2004; Shah
et al., 2004; Tremblay et al., 2005; Um et al., 2004). It has
been speculated that such a system may have evolved to pre-
vent cells from actively taking up nutrients in response to insulin
under conditions of nutrient overload, such as in the obese
setting (Um et al., 2004).
S6K1
Insulin-induced anabolic responses, most notably ribosome
biogenesis and protein synthesis, are dependent on nutritional
state (Hay and Sonenberg, 2004). In turn, these responses rely
in part on S6K1, a member of the A, G, and C family of serine/
threonine protein kinases (Hanks and Hunter, 1995; Manning
et al., 2002). In mammals there are two isoforms of S6K1, which
are produced from the same transcript by alternative initiation
translation start sites (Grove et al., 1991; Reinhard et al.,
1992). The larger isoform, termed S6K1L, contains an amino-
terminal 23 amino acid extension (Grove et al., 1991; Reinhard
et al., 1992), which localizes S6K1L to the nucleus. In contrast,
the shorter form, S6K1S, appears to be largely localized to the
cytoplasm (Reinhard et al., 1994). Findings to date would sug-
gest that the two isoforms are controlled in a similar manner
and are thus collectively referred to here as S6K1. Deletion of
the S6K1 gene in mice led to the discovery of a second S6
kinase gene (Shima et al., 1998), highly identical to the S6K1
gene, termed S6K2 or S6Kb (Shima et al., 1998; Gout et al.,
1998; Saitoh et al., 1998). S6K2 shows 82% identity in the cat-
alytic domain and in the linker and autoinhibitory domains with
S6K1 (Gout et al., 1998; Saitoh et al., 1998; Shima et al.,
1998). Moreover, there are apparently two isoforms, derived by
alternate splicing, that we have termed here S6K2L, the larger,
and S6K2S, the smaller (Gout et al., 1998; Lee-Fruman et al.,
1999). Both S6K1 and 2 are widely expressed. S6K1 is identicalOI 10.1016/j.cmet.2006.05.003 393
R E V I E WFigure 1. Model depicting mTOR/S6K1 signaling pathway in response to nutrients and insulin
The mTOR/S6K1 signaling pathway mediates various biological effects of nutrients, insulin, and energy. Nutrients such as amino acids and glucose increase hVps34
activity, stimulating the production of PI3P. PI3P recruits proteins containing FYVE or PX domains to endosomal membranes. The mTOR/S6K1 signaling pathway is
also activated by insulin. Insulin binds the insulin receptor and leads to an increase in tyrosine phosphorylation of IRS1. IRS1-associated class 1 PI3K increases the
production of PIP3, recruiting PDK1 and PKB to the plasma membrane. PKB is activated by the concerted action of the rapamycin-insensitive rictor-mTOR complex
and PDK1. Activated PKB phosphorylates and subsequently inactivates TSC2, a GTPase-activating protein, leading to an increase in GTP bound Rheb. Rheb-GTP
increases mTOR activity and further facilitates the phosphorylation of S6K1 and 4E-BP1. The mTOR/S6K1 signaling pathway can sense energy levels either directly,
through mTOR, or indirectly, through AMPK. Energy stress, such as fasting or lowering cellular ATP concentration, induces AMPK activation, leading to a PKB-independent
TSC2 phosphorylation, which is thought to activate TSC2. This activation of TSC2 results in an increase in GDP bound Rheb and subsequent decrease in mTOR activity.
Hypoxia induces Redd1/2, leading to a decrease of mTOR activity in a pathway parallel to the AMPK. Dashed lines indicate an interaction with an unknown mechanism. Red
lines indicate inhibitory signal to the mTOR/S6K1 pathway.in amino acid sequence in all mammalian species examined to
date, whereas S6K2 displays a high degree of identity (Mon-
tagne and Thomas, 2004). The homology extends to inverte-
brates in which a single-copy ortholog was identified for the
S6Ks in Drosophila melanogaster (Stewart et al., 1996; Watson
et al., 1996). Researchers have also found single-copy orthologs
in Caenorhabditis elegans (Long et al., 2002), Aplysia californica
(Khan et al., 2001), Artemia franciscana (Santiago and Sturgill,
2001), and Schizosaccharomyces pombe (Matsuo et al., 2003).
In addition, two S6K1 and S6K2 orthologs are present in Arabi-
dopsis thaliana (Turck et al., 1998), indicating that S6 kinases
are evolutionarily conserved in plants. Downstream a number
of effectors have been identified, including 40S ribosomal pro-
tein S6 (Montagne and Thomas, 2004), protein synthesis initia-
tion factor 4B (Raught et al., 2004), and elongation factor 2 kinase
(Proud, 2004) (Figure 1).394Insulin signaling to S6K1
Insulin induces S6K1 activation through a canonical signal trans-
duction pathway (Hay and Sonenberg, 2004; Montagne and
Thomas, 2004), which is initiated by insulin receptor (IR) auto-
phosphorylation and the recruitment and phosphorylation of
IR substrates 1 and 2 (IRS1/2) at multiple tyrosine residues (Fig-
ure 1) (White, 1998). A subset of these sites serve as docking
motifs for the p85 regulatory subunit of class 1, phosphoinosi-
tide 3-kinase (PI3K). This leads to the production of phosphati-
dylinositide-3, 4, 5-P3 (PIP3), which binds to the pleckstrin
homology (PH) domain of protein kinase B (PKB), disrupting its
interaction with the catalytic domain. The phosphoinositide-
dependent protein kinase 1 (PDK1) can then phosphorylate
PKB T308 and activate the kinase (Alessi et al., 1997; Stokoe
et al., 1997) (Figure 1). PKB subsequently phosphorylates
Tuberous Sclerosis Complex protein 2 (TSC2), inducing theCELL METABOLISM : JUNE 2006
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and TSC1 (Dan et al., 2002). In the active state, TSC1/2, through
the GTPase-activating domain of TSC2, drives the small GTPase
Ras homolog enriched in brain (Rheb) into the inactive GDP
bound state (Li et al., 2004). Recent studies indicate that GTP
bound Rheb acts directly on the mammalian target of rapamycin
(mTOR) (Long et al., 2005a) (Figure 1). mTOR is known to exist
in an evolutionarily conserved, rapamycin-sensitive complex
with two additional proteins, regulatory-associated protein of
mTOR (raptor) and G protein b-subunit-like protein (GbL) (Hay
and Sonenberg, 2004). It is presumably this complex (mTOR
complex 1) that mediates S6K1 phosphorylation at a number of
residues, as judged from in vitro studies (Isotani et al., 1999).
These phosphorylation sites include T389, whose phosphoryla-
tion allows PDK1 to phosphorylate S6K1 T229 and activate
the kinase (Alessi et al., 1998; Pullen et al., 1998). The ability of
mTOR to mediate S6K1 activation is controlled by raptor, which
recognizes S6K1 through its amino-terminal TOR signaling
(TOS) motif (Schalm and Blenis, 2002). However, recent studies
show that mTOR also exists in a second rapamycin-resistant
signaling complex with GbL and a protein termed AVO3, or rapa-
mycin-insensitive companion of mTOR (rictor), rather than rap-
tor, and that this complex mediates the phosphorylation of
S473, the equivalent site to S6K1 T389. In concert with PDK1
phosphorylation of T308, this leads to PKB activation (Sarbas-
sov et al., 2005) (Figure 1). Thus, the role of the mTOR/rictor/
GbL complex (mTOR complex 2) in PKB activation places it as
a key upstream effector in S6K1 activation (Figure 1).
Amino acids and glucose
It has become evident over the last few years that mitogens and
hormones, such as insulin, alone are insufficient to drive S6K1
activation in the absence of nutrients such as amino acids and
glucose (Montagne and Thomas, 2004). These observations in-
dicate that the insulin-induced signaling pathway is integrated
with inputs from ambient nutrients to regulate mTOR complex
1 function and control S6K1 activation. The importance of nutri-
ents in S6K1 signaling was first hinted at from studies in macro-
autophagy, a process in which portions of cytoplasm are
sequestered into autophagosomes for transport to lysosomes
for degradation and recycling of cellular constituents (Klionsky
and Emr, 2000). In this way macroautophagy plays a critical
role in maintaining cellular metabolic homeostasis in response
to nutrient deprivation. Initially, Meijer and colleagues demon-
strated that inhibition of macroautophagy by amino acid addition
was paralleled by an increase in S6 phosphorylation, which they
attributed to S6K1 activation (Blommaart et al., 1995). Moreover,
they showed that amino acid inhibition of macroautophagy was
in part suppressed by rapamycin, a fungicide produced by
Streptomyceshygroscopicus (Dennis and Thomas, 2002). Rapa-
mycin acts by forming an inhibitory complex with the immuno-
philin, FK506 binding protein 12 (FKBP12), which binds to and
disrupts mTOR complex 1 signaling (Hay and Sonenberg,
2004; Montagne and Thomas, 2004). Consistent with these
findings, it was subsequently demonstrated that amino acid-
dependent S6K1 activation is mTOR dependent (Hara et al., 1998;
Iiboshi et al., 1999), with a number of studies pointing to the
importance of branched-chain amino acids, especially leucine
(Hay and Sonenberg, 2004; Kimball and Jefferson, 2004). How-
ever, it should be noted that recent reports suggest that thereCELL METABOLISM : JUNE 2006may be mTOR-independent routes involved in amino acid-
induced autophagy inhibition (see Codogno and Meijer, 2005).
Energy
mTOR complex 1 signaling to S6K1 is also sensitive to small
changes in the physiological levels of ATP, independent of alter-
ations in amino acid levels (Dennis et al., 2001). Here, treatment
with the mitochondrial complex 1 inhibitor rotenone was shown
to induce a small reduction in intracellular ATP levels and, in par-
allel, lead to a strong attenuation of insulin-induced S6K1 activa-
tion (Dennis et al., 2001). Consistent with the proposal that ho-
meostatic levels of ATP directly regulate mTOR signaling
(Dennis et al., 2001), mTOR’s apparent Km for ATP is similar
to intracellular ATP concentrations (Gribble et al., 2000). How-
ever, subsequent studies reported that energy depletion in-
hibited mTOR signaling through AMP-activated kinase (AMPK)
phosphorylation of TSC2 (Corradetti et al., 2004; Inoki et al.,
2003; Shaw et al., 2004) (Figure 1). This observation would
seem to support a pivotal role for AMPK in switching between
energy-consuming and energy-sparing processes by sensing
changes in the intracellular AMP/ATP ratio (Figure 1) (Carling,
2004). However, it is not known how AMPK phosphorylation of
TSC2 enhances the ability of TSC1/2 to inhibit downstream sig-
naling to Rheb (Inoki et al., 2003). Indeed, this site is not con-
served in the Drosophila homolog of TSC2, dTSC2 (Ito and
Rubin, 1999). Moreover, the role of AMPK has been placed into
question by recent studies showing that the hypoxia-inducible
gene, regulated in development and damage responses
(REDD1), is also induced by energy depletion and that this leads
to inhibition of mTOR complex 1 signaling to S6K1, but in a man-
ner independent of AMPK (Sofer et al., 2005) (Figure 1). In sup-
port of this notion, absence of REDD1 does not alter AMPK
activation, or its apparent ability to phosphorylate TSC2; how-
ever it ablates the inhibitory effects of energy depletion on
mTOR complex 1 signaling to S6K1 (Sofer et al., 2005). The
mechanism by which REDD1 mediates the effects of energy
depletion on mTOR complex 1 signaling to S6K1 is unknown,
but it appears to require TSC2 (Sofer et al., 2005). It should
also be noted that the role of TSC1/2 in regulating the energy
input to mTOR complex 1 and S6K1 activation has been chal-
lenged by Smith et al., who found that treatment of TSC2-defi-
cient cells with 2-deoxyglucose still led to the inactivation of
S6K1 (Smith et al., 2005). These findings raise the possibility
that AMPK phosphorylation of TSC2 is not necessary for re-
sponses to energy challenge and that additional mechanisms
may be implicated (see below).
Negative feedback loop
In parallel studies, it has become increasingly evident that S6K1
may also be implicated in a negative feedback loop to suppress
insulin signaling. Such a role for S6K1 was first supported by the
observation that amino acids inhibit insulin-induced PI3K signal-
ing (Patti, 1999), a response later shown to be blunted by rapa-
mycin (Tremblay and Marette, 2001). In parallel, genetic and
biochemical studies in Drosophila showed that the S6K1/2 or-
tholog, dS6K, is a negative effector of dPKB (Radimerski et al.,
2002a, 2002b). As larval growth is exquisitely sensitive to nutri-
ents (Oldham et al., 2000), this raised the possibility that the neg-
ative effects of amino acids on insulin signaling may be medi-
ated by S6K1 (Radimerski et al., 2002a). Consistent with these
findings, S6K12/2 mice maintained on a high-fat diet (HFD)395
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despite the fact that insulin receptors desensitize in such mice
(Um et al., 2004). That this response is due to loss of S6K1 is
shown by the finding that siRNA knockdown of S6K1 protein
in cells has no effect on insulin-induced receptor tyrosine auto-
phosphorylation but potentiates insulin-induced PKB phosphor-
ylation (Um et al., 2004). These studies suggested that S6K1
elicits a selective inhibitory effect on PKB activation at a point
downstream of the insulin receptor. Further analyses revealed
that phosphorylation of IRS1 S307 and S632 was reduced in
S6K12/2mice on a high-fat diet and in S6K1 siRNA-treated cells
(Um et al., 2004), sites known to be elevated in animal models of
obesity and in muscle from type 2 diabetics (Bouzakri et al.,
2003). Moreover, whereas PKB activity was blunted in animals
fed a HFD and in two genetic mouse models of obesity, S6K1
activity was highly elevated (Um et al., 2004). These findings
suggested that S6K1 may positively affect IRS1 serine phos-
phorylation, leading to inhibition of PKB signaling and insulin
resistance (Figure 3). This hypothesis was substantiated by
results demonstrating in TSC22/2 mouse embryonic fibroblasts
(MEFs), which exhibit constitutive S6K1 activation, that IRS1 is
hyperphosphorylated and degraded (Harrington et al., 2004;
Shah et al., 2004). These studies revealed that IRS1 S302, which
is proximal to the IRS1 phosphotyrosine binding (PTB) domain
and contains an S6K1 recognition motif (Flotow and Thomas,
1992), is phosphorylated by S6K1 (Harrington et al., 2004) (Fig-
ure 3). Moreover, evidence was provided that phosphorylation
of this site disrupts the ability of the PTB domain to interact
with the activated IR, which would lead to decreased insulin sig-
naling (Harrington et al., 2004). These findings support the
model that S6K1 mediates IRS1 serine phosphorylation, dis-
rupting its interaction with IR and leading to its degradation.
Degradation of phosphorylated IRS1 is mediated by its associ-
ation with a 14-3-3 family member, which relocates IRS1 from
low-density microsomes to the cytosol (Figure 3), where it can
be accessed and degraded by the 26S proteasome (Craparo
et al., 1997). However, it should be noted that others have re-
ported that both IRS1 S302 and S307 phosphorylation are nec-
essary, but not sufficient, for mediation of this response (Werner
et al., 2004), suggesting that additional phosphorylation sites
are involved. It will be of interest to determine whether in
S6K12/2 mice phosphorylation of IRS1 S302 is abrogated and
whether phosphorylation at this site is involved in a predisposi-
tion for insulin resistance in vivo.
In parallel, the Lamb and Hunter groups also demonstrated
that in TSC22/2 cells IRS1 mRNA levels were reduced and re-
stored by rapamycin treatment, with the latter effect blocked
by actinomycin D (Harrington et al., 2004; Shah et al., 2004). Fur-
thermore, Harrington et al. have shown that suppression of
S6K1 mimics the effect of rapamycin treatment and restores
IRS1 mRNA levels (Harrington et al., 2004). This raises the ques-
tion of whether IRS1 is the only target of mTOR, through S6K1,
by which mTOR contributes to the negative feedback loop to
downregulate PKB. Shah et al. have shown that IRS2 protein
levels are also reduced in TSC22/2 cells (Shah et al., 2004). Con-
sistent with this finding, Rhodes and colleagues have recently
shown that chronic activation of mTOR signaling by glucose
and IGF-1 or adenoviral-mediated expression of a constitutively
activated mTOR construct increases serine/threonine phos-
phorylation of IRS2 and its degradation by the proteasome, an
effect blocked by rapamycin or lactacystin (Briaud et al.,3962005). Thus, in delineating the role of S6K1 in the regulation of
insulin signaling it will be necessary to establish the extent to
which IRS1 and 2 contribute to this response.
A novel nutrient signaling pathway
The emerging paradigm by which nutrient overload can lead to
insulin resistance though activation of mTOR complex 1 signal-
ing to S6K1 (Patti and Kahn, 2004; Um et al., 2004) has under-
scored the importance of understanding where nutrients enter
the mTOR complex 1 signaling pathway. Contrary to earlier
models, which suggested that nutrients acted through TSC1/2,
recent findings support a model in which nutrients act on
mTOR complex 1 signaling, independently of TSC1/2 (Nobukuni
et al., 2005; Smith et al., 2005). Moreover, as Rheb-GTP levels
do not drop in TSC12/2 or TSC22/2 cells following amino acid
withdrawal (Nobukuni et al., 2005; Roccio et al., 2006), although
S6K1 is inactivated, it seemed likely that the major amino acid
input that mediated S6K1 activation resided on a pathway par-
allel to that of the TSC1/2-Rheb signaling axis (Nobukuni et al.,
2005). Although it has been shown that amino acid withdrawal
can lead to a transient drop in Rheb-GTP levels in some cell
types, S6K1 remains inactivated (Roccio et al., 2006). Earlier
studies demonstrated that wortmannin, a potent class 1 PI3K in-
hibitor, blocks amino acid-induced mTOR complex 1 signaling,
as judged by S6K1 activation (Hara et al., 1998; Iiboshi et al.,
1999). Given that amino acids do not induce PKB activation
(Hara et al., 1998; Nobukuni et al., 2005), this implies that the
wortmannin-sensitive amino acid input to mTOR complex 1 is
not via inhibition of class 1 PI3K. Consistent with these argu-
ments, siRNA depletion of class 1 PI3K blocked insulin-induced
S6K1 activation but had no effect on amino acid-mediated S6K1
activation (Nobukuni et al., 2005). These observations led to the
finding that the wortmannin-sensitive target is class 3 PI3K or
human class III phosphatidylinositol 3-kinase, hVps34 (Figures
1 and 3), as siRNA knockdown of hVps34 blocks amino acid-
and insulin-induced S6K1 activation but has no effect on PKB
activation (Byfield et al., 2005; Nobukuni et al., 2005). Moreover,
stimulation of cells with amino acids increases hVps34 activity
and the production of phosphatidylinositol 3-phosphate (PI3P),
the product of hVps34 (Byfield et al., 2005; Nobukuni et al.,
2005), a response that is not altered in TSC22/2 cells, consistent
with the state of S6K1 activation (Nobukuni et al., 2005) (Figures
1 and 3). PI3P mediates the recruitment of proteins containing
Fab1/YOTB/ZK632.12/Vac1/EEA1 (FYVE) or PI3P-targeting-
phox homology (PX) domains to endosomal membranes (Lem-
mon, 2003), with PI3P-rich microdomains recently having been
shown to act as signaling platforms (Burda et al., 2002; Gonza-
lez-Gaitan and Stenmark, 2003; Miaczynska et al., 2004). Con-
sistent with the role of hVps34 in mediating the amino acid input
that leads to S6K1 activation, this response is blocked by the
overexpression of a dominant interfering cDNA containing two
FYVE domains (Nobukuni et al., 2005). Interestingly, Backer
and colleagues have also shown that energy as well as osmotic
stress regulate hVps34 activity ina manner similar to that of amino
acid withdrawal, suggesting that hVps34 may represent a
common nutrient sensor for S6K1 activation (Byfield et al., 2005).
The question that arises from these studies concerns the
identity of the mechanism by which hVps34 exerts these effects
and how they are integrated with those of the insulin signaling
pathway to mediate S6K1 activation. It has been shown that
either amino acid or glucose withdrawal drives the mTORCELL METABOLISM : JUNE 2006
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measured by the stronger binding of raptor to mTOR and the in-
ability of the complex to phosphorylate S6K1 in vitro (Kim et al.,
2002). In contrast, re-addition of amino acids reverts this com-
plex into a so-called ‘‘active conformation,’’ reflected by
a weaker interaction of raptor with mTOR and the restored ability
to signal to S6K1 in vitro (Kim et al., 2002). It has also been
shown that in contrast to raptor, Rheb binds to the mTOR cata-
lytic domain and that its binding is reversibly inhibited by amino
acid withdrawal, regardless of GTP or GDP loading (Long et al.,
2005a, 2005b). Though highly speculative, it may be that hVps34
drives the mTOR complex 1 into an active conformation, allow-
ing Rheb to bind. In summary, these most recent studies have
provided a framework for investigating the underlying molecular
signaling mechanisms by which the ancient nutrient effector
mTOR complex 1 signaling pathway has been integrated with
that of humoral or insulin signaling to control growth during the
rise of metazoans (Figures 1 and 3).
S6K12/2 mice have impaired glucose homeostasis
A deeper understanding of the role of S6K1 as a nutrient effector
originally arose in studies of mice in which the gene had been
deleted (Shima et al., 1998). Such mice displayed a lean pheno-
type and were approximately 20% smaller at birth, an effect
which was more pronounced during embryogenesis (Shima
et al., 1998). Moreover, in all tissues examined in S6K12/2
mice, S6K2 transcripts were upregulated, although this did
not rescue the impaired growth phenotype associated with
S6K12/2 mice (Shima et al., 1998). Consistent with this finding,
mice lacking both S6K1 and S6K2 are no more severely affected
in growth than S6K12/2 mice, although they show a sharp re-
duction in viability due to perinatal lethality (Pende et al.,
2004). In addition to S6 phosphorylation, proliferation as well
as the translation of 50 terminal oligopyrimidine (50 TOP) mRNA
were intact in S6K12/2 MEFs (Shima et al., 1998). The 50 TOP
mRNAs encode for components of the translational apparatus
(Meyuhas et al., 1996). The fact that their expression was un-
affected in S6K12/2 mice indicated that the small body size
phenotype did not stem from reduction in the amount of trans-
lational machinery. The phenotype of these mice and the sensi-
tivity of S6K1 activation to amino acids (Hara et al., 1998) and
glucose (Hugl et al., 1998) led to the finding that S6K12/2 mice
are mildly glucose intolerant and have reduced levels of circulat-
ing insulin (Pende et al., 2000). Reduced insulin levels result from
a selective reduction in b cell volume, which has a pronounced
effect on both pancreatic insulin content and insulin secretion
(Pende et al., 2000) (Figure 2). These findings also suggest
that the function of S6K1 in pancreatic b cell growth and insulin
secretion is distinct from that of S6K2. Seemingly consistent
with this finding, recent studies show that knockin mice, in which
the wild-type allele of ribosomal protein S6 was replaced by
a mutant having the five sites of serine phosphorylation changed
to alanines, exhibit reduced pancreatic b cell size and glucose
intolerance (Ruvinsky et al., 2005). However, despite the appar-
ent similarity in phenotype between S6K12/2 mice and mutant
S6 knockin mice, it is still unclear whether reduced pancreatic
b cell size in S6K12/2 mice can be attributed to reduced S6
phosphorylation, as the major S6 kinase appears to be S6K2
in all tissues examined to date (Pende et al., 2004), including
pancreas (M. Pende, S.H.U., and S.C. Kozma, unpublished
data). In addition, it has yet to be determined whether reducedCELL METABOLISM : JUNE 2006pancreatic b cell size in S6K1-deficient mice, or in S6 knockin
mice, is due to a cell-autonomous defect.
Despite the fact that S6K12/2 mice are mildly glucose intoler-
ant and display hypoinsulinemia, they maintain normal fasting
and feeding glucose levels in the fasting and fed states, which
initially led to the hypothesis that such mice may be more sensi-
tive to insulin in their peripheral tissues than wild-type mice
(Pende et al., 2000). This speculation eventually led to the finding
of the negative feedback loop whereby insulin-induced S6K1
activation reduced insulin signaling (Um et al., 2004). In the ab-
sence of this signaling regulation, S6K12/2mice have enhanced
insulin sensitivity as a function of either age or diet (Um et al.,
2004). This distinct phenotype, hypoinsulinemia coupled with in-
creased insulin sensitivity, raised the question of whether such
mice would be protected against diet-induced obesity (Um
et al., 2004). In fact, when S6K12/2 mice were placed on HFD,
the rate of weight accumulation was dramatically reduced as
compared to wild-type mice, consistent with MRI analyses dem-
onstrating a striking reduction in fat depots (Um et al., 2004) (Fig-
ure 2). Assessment of total fat depots revealed that the body fat
index for S6K12/2 mice increased by only 15%–20% over this
period whereas the value for wild-type mice doubled (Um
et al., 2004). This decrease in fat accumulation appears to be
due to a dramatic rise in lipolysis in adipose and energy combus-
tion in both adipose and muscle (Um et al., 2004). Thus, S6K12/2
mice are protected against diet-induced obesity due to a sharp
increase in lipolysis and metabolic rate, which is linked to
enhanced oxidative phosphorylation (Um et al., 2004).
Adipose tissue
That S6K1 plays an important anabolic role in insulin-responsive
tissues has been revealed by specific phenotypes displayed
by S6K12/2 mice. As stated above, S6K12/2 mice exhibit
Figure 2. The role of S6K1 in nutrient- and insulin-responsive tissues
Insulin, amino acids, and energy activation of S6K1 signaling induce anabolism, in-
cluding lipid accumulation in adipose tissue, skeletal muscle hypertrophy, pancre-
atic b cell growth, and protein synthesis. S6K1 signaling also suppresses catabolic
events such as lipolysis in adipose tissue and fatty acid oxidation in muscle, both
of which generate ATP.397
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of preadipocytes and adipose tissue mass (Um et al., 2004). A
link between S6K1 and adipogenesis was first suggested in
studies that showed that rapamycin inhibits clonal expansion
and adipocyte differentiation and in parallel inhibits the expres-
sion of CCAAT/enhancer binding proteina (C/EBPa), a transcrip-
tion factor required for 3T3-L1 cell differentiation (Yeh et al.,
1995). Following this initial observation it was found that rapa-
mycin can also disrupt adipogenesis in primary human adipo-
cytes independent of its antiproliferative effect on clonal expan-
sion (Bell et al., 2000) since primary human adipocytes undergo
differentiation in the absence of clonal expansion. In support
of this observation, it was recently reported that the inhibitory
effect of rapamycin persists throughout the process of adipo-
cyte differentiation (Cho et al., 2004). This significantly reduces
expression of most adipocyte marker genes, including Peroxi-
some Proliferator-Activated Receptor g (PPARg) and Fatty
Acid Synthase (FAS), and decreases intracellular lipid accumu-
lation (Cho et al., 2004). Interestingly, it was shown that 3T3-L1
adipocytes subjected to amino acid deprivation, like rapamycin
treatment, suppresses the induction of C/EBPa, providing a
potential link between nutrients and adipogenesis transcrip-
tional programs. Both amino acid deprivation and rapamycin
treatment specifically disrupt the positive transcriptional feed-
back loop between PPARg and C/EBPa, two key transcription
factors involved in mediating adipogenesis by directly targeting
the transactivation activity of PPARg (Kim and Chen, 2004).
Taken together, these findings would support a model whereby
reduced adipogenesis in response to rapamycin treatment may
arise from impaired S6K1 signaling. Such impairment could be
induced by one of two adipogenic stimuli, fatty acids and/or
PPARg agonists, and amino acid availability. However, whereas
a rapamycin-resistant mutant of mTOR conferred rapamycin re-
sistance on both adipogenesis and C/EBPa induction, neither
a rapamycin-resistant mTOR kinase dead mutant nor a rapamy-
cin-resistant S6K1 mutant conferred rapamycin resistance on
either response (Kim and Chen, 2004). These studies could be
interpreted in two ways. First, as the rapamycin-resistant
S6K1 mutant is presumably regulated by mTOR complex 2
rather than mTOR complex 1 (Ali and Sabatini, 2005), one pos-
sibility is that this construct may not faithfully mimic wild-type
S6K1 function. On the other hand, the effects observed on adi-
pogenesis in S6K12/2mice may be due to developmental or hu-
moral stimuli, such that the effects observed on adipogenesis
are not attributable to a cell-autonomous effect on adipocytes.
It will be important to resolve such issues in future studies.
Muscle
Like b cells and adipocytes, muscle growth, or hypertrophy, also
appears to be strongly affected in S6K12/2 mice. Hypertrophy
of muscle is characterized by an increase in the size of myofib-
ers, which can occur as an adaptive response to load-bearing
exercise. PKB and mTOR signaling are upregulated during mus-
cle hypertrophy and downregulated during muscle atrophy
(Bodine et al., 2001). Consistent with this, hypertrophy in cell
culture and in compensatory animal models is blocked by rapa-
mycin, and these inhibitory effects appear to be mediated by in-
hibition of S6K1 (Ohanna et al., 2005) (Figure 2). This conclusion
is based on recent results of Pende and colleagues, who
showed that S6K12/2 mice exhibit an atrophy-like phenotype
in skeletal muscle without having altered PKB or eIF4E binding398proteins 1/2 (4E-BP1/2) activation (Ohanna et al., 2005). More-
over, they further demonstrated that S6K1 mediates the IGF1-
induced skeletal muscle hypertrophy phenotype, which is
dependent on mTOR but does not affect muscle cell-cycle pro-
gression induced by constitutively activated PKB (Ohanna et al.,
2005). Similar results have been obtained in C2C12 cells (Park
and Chen, 2005). The fact that the impaired hypertrophic re-
sponse to IGF1 in S6K12/2 cells does not correlate with S6
phosphorylation or overexpression of S6K2 would argue for
a novel unidentified S6K1 substrate (Ohanna et al., 2005). Inter-
estingly, Richardson et al. have shown that the S6K1 Aly/REF-
like target (SKAR), an RNA binding protein, is a specific target
for S6K1, but not for S6K2, in controlling cell growth (Richardson
et al., 2004). However, whether SKAR is involved in skeletal
muscle hypertrophy has not been studied.
Figure 3. Homeostasis versus nutrient overload
In a homeostatic setting, as nutrients and amino acids are consumed, mTOR/S6K1
activity participates in mediating cell growth. In contrast, under conditions of
nutrient overload associated with the obese state, constitutive activation of
mTOR/S6K1 signaling leads to desensitization of insulin signaling through IRS1
serine phosphorylation and inhibition of IRS1 transcription. Serine phosphorylation
of IRS1 associates with a 14-3-3 family member, localizes IRS1 to cytosol, and
subsequently leads to proteasomal degradation. IRS1 also associates suppressor
of cytokine signaling-1 (SOCS1) and SOCS3, which form an E3 ubiquitin ligase
complex leading to the proteasome degradation pathway.CELL METABOLISM : JUNE 2006
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The importance of nutrient overload in type 2 diabetes is
strongly supported by recent intervention trials showing that
weight loss through exercise or dietary modifications can
reduce the incidence of type 2 diabetes by 60% (Knowler
et al., 2002; Tuomilehto et al., 2001). As plasma concentrations
of amino acids are increased in obesity (Felig et al., 1969, 1970,
1974) and amino acids drive S6K1 activation (Hara et al., 1998;
Iiboshi et al., 1999; Nobukuni et al., 2005), it is hypothesized that
insulin resistance in obese humans may in part be mediated by
S6K1 phosphorylation of IRS1 (Um et al., 2004) (Figure 3). To ad-
dress the metabolic mechanisms by which elevated amounts of
amino acids lead to insulin resistance, the effects of amino acid
infusion in humans has been studied in both liver and muscle
through the use of 31P/13C nuclear magnetic resonance spec-
troscopy (Krebs et al., 2002, 2003). In liver, increased amounts
of circulating amino acids were found to increase gluconeogen-
esis (Krebs et al., 2003). This increase was found to be indepen-
dent of the ability of amino acids to induce the secretion of
glucagon and insulin but primarily due to the fact that they serve
as substrates to drive gluconeogenesis. Although the amino
acid-induced increase in insulin secretion protects against hy-
perglycemia induced by endogenous glucose production in
healthy individuals, impaired insulin secretion unmasks the con-
tribution of amino acids through increased gluconeogenesis
(Krebs et al., 2003). Although S6K1 is highly phosphorylated in
livers of obese rodents, and this effect as well as insulin resis-
tance are reversed by the administration of rapamycin (Ueno
et al., 2005), it is not known whether amino acids contribute di-
rectly to hepatic insulin resistance through S6K1 activation (Fig-
ure 2).
In skeletal muscle, insulin stimulation leads to the uptake of
glucose, through PKB-mediated translocation of the glucose
transporter-4 to the cell surface (Figure 3). Like free fatty acids,
many amino acids are metabolized to acetyl-coenzyme A and
oxidized in mitochondria. In this way amino acids might be spec-
ulated to compete with glucose as an energy source at the level
of b oxidation in mitochondria, leading to hyperglycemia (see
Krebs, 2005). Consistent with this model, an approximate
2-fold rise in serum plasma amino acid concentrations is paral-
leled by an approximately 25% reduction in insulin sensitivity
(Krebs et al., 2002). However, the reduction in insulin sensitivity
is preceded by a decrease in the rise of intramuscular glucose-6
phosphate and followed by a sharp drop in glycogen synthesis,
arguing that the amino acids are not competing as substrates
but are directly inhibiting glucose transport and phosphorylation
(Krebs et al., 2002). Compatible with this data and those in mice
(Um et al., 2004), recent studies in humans have also shown that
the amino acid infusion-induced inhibition of insulin-stimulated
glucose disposal in skeletal muscle is paralleled by IRS1 phos-
phorylation at S312 and S636/639 (S307 and S632/635 in the
mouse) and an inhibition of insulin-induced PI3K activation
(Tremblay et al., 2005) (Figure 3). Therefore, excess amino acids
contribute to insulin resistance by inhibiting glucose uptake, one
of the earliest defects responsible for the development of type 2
diabetes (Martin et al., 1992). Moreover, impaired glucose up-
take appears to be mediated through phosphorylation of IRS1
by S6K1 (Tremblay et al., 2005), a system that may have evolved
to suppress insulin signaling under conditions of nutrient over-
load (Figure 3). Future studies will determine whether deregula-
tion of the nutrient signaling pathway is due to genetic alter-CELL METABOLISM : JUNE 2006ations that predispose to the early onset of obesity, and
whether insulin resistance and/or excess nutrient intake cause
constitutive activation of this pathway leading to desensitization
of class 1 PI3K-dependent insulin signaling in individuals.
In conclusion, understanding the mechanisms by which
amino acids impact on the nutrient-sensitive signaling pathways
through such molecules as hVps34, leading to S6K1 activation,
may provide novel strategies for the treatment of insulin resis-
tance.
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